CYP2D6 Cancer Research Results

CYP2D6, Cytochrome P450 Family 2 Subfamily D Member 6: Click to Expand ⟱
Source:
Type: drug-metabolism / pharmacogenetic target

CYP2D6 - Cytochrome P450 Family 2 Subfamily D Member 6

Type: Cytochrome P450 monooxygenase / drug-metabolism enzyme / pharmacogenetic marker

Function: CYP2D6 is a highly polymorphic cytochrome P450 enzyme responsible for oxidative metabolism of numerous drugs and xenobiotics. Genetic variation produces poor, intermediate, normal, and ultrarapid metabolizer phenotypes and can substantially alter drug exposure, efficacy, and toxicity.

Cancer: ↕ Context-dependent. CYP2D6 can either activate or inactivate pharmacologically active compounds and therefore has treatment-specific effects rather than a uniform oncogenic or tumor-suppressive role. In estrogen-receptor-positive breast cancer, CYP2D6 contributes importantly to conversion of tamoxifen to the potent active metabolite endoxifen; reduced CYP2D6 activity can result in lower endoxifen concentrations and potentially reduced tamoxifen efficacy.
Scientific Papers found: Click to Expand⟱
7565- HYP,    Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review
- Review, AD, NA
*Inflam↓, *antiOx↑, *neuroP↑, *lipid-P↓, *ROS↓, *IL1β↓, *IL6↓, *IL8↓, *TNF-α↓, *MDA↓, *BAX↓, *Casp3↓, *Catalase↑, *SOD↑, *GSH↑, *BDNF↑, *TrkB↑, *NGF↑, *BDNF↑, *NF-kB↓, *AChE↓, *H2S↑, Casp3↑, Apoptosis↑, NF-kB↓, AMPK↑, HO-1↑, MAPK↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, SOD?, Catalase↓, NRF2↓, NQO1↓, HO-1↓, Bcl-2↓, TumCCA↑, FOXO1↑, TumAuto↑, Akt↓, mTOR↓, P70S6K↓, BMP7/OP1↓, *cardioP↑, *hepatoP↑, *antiCG↑, *AntiThr↑, *Diar↓, *AntiFungal↑, *CYP2D6↓, *PDGFR-BB↓, *PDGFRB↓, *toxicity↓, *Half-Life↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   HO-1↓, 1,   HO-1↑, 1,   NQO1↓, 1,   NRF2↓, 1,   SOD?, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,   MAPK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FOXO1↑, 1,   mTOR↓, 1,   P70S6K↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiCG↑, 1,   CYP2D6↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

H2S↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PDGFRB↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

PDGFR-BB↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 2,   NGF↑, 1,   TrkB↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Diar↓, 1,  
Total Targets: 33

Scientific Paper Hit Count for: CYP2D6, Cytochrome P450 Family 2 Subfamily D Member 6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1661  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page